Suppr超能文献

口服泰舒达在泌乳素瘤患者中的药代动力学

Pharmacokinetics of oral terguride in patients with a prolactinoma.

作者信息

Lapka R, Marek J, Rejholec V, Franc Z

出版信息

Eur J Clin Pharmacol. 1986;30(3):363-5. doi: 10.1007/BF00541546.

Abstract

The pharmacokinetics of oral terguride 1 mg was evaluated in a single-dose study in 8 patients with a prolactinoma and one with acromegaly. A radioreceptor assay was used to measure the plasma levels of terguride. The peak plasma concentration (2.3 +/- 0.7 ng/ml, mean +/- SEM) was attained within 1 h of drug administration. Moment analysis gave a mean residence time of 4.3 +/- 0.6 h. Plasma prolactin was also determined by radioimmunoassay. The plasma prolactin was reduced to 30 +/- 3% of its pretreatment value after 4 h.

摘要

在一项单剂量研究中,对8例催乳素瘤患者和1例肢端肥大症患者评估了口服1毫克泰舒达的药代动力学。采用放射受体分析法测定血浆中泰舒达的水平。给药后1小时内达到血浆峰浓度(2.3±0.7纳克/毫升,平均值±标准误)。矩量法得出平均驻留时间为4.3±0.6小时。还通过放射免疫分析法测定血浆催乳素水平。4小时后,血浆催乳素降至治疗前值的30±3%。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验